Buscar
Mostrando ítems 61-70 de 120
Clinical Approaches to Preserve beta-Cell Function in Diabetes
(SPRINGER-VERLAG BERLIN, 2010)
In type 2 diabetes (DM2) there is progressive deterioration in beta-cell function and mass. It was found that islet function was about 50% of normal at the time of diagnosis and reduction in beta-cell mass of about 60% at ...
Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
(Sociedad Médica de Santiago, 2015)
Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its
efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is
not well known. Aim: To assess the safety profile and ...
Safety and efficacy of vildagliptin in real life chilean diabetic patients Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
(Sociedad Medica de Santiago, 2015)
© 2015, Sociedad Medica de Santiago. All rights reserved. Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not ...
Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
(Soc. Médica de Santiago, 2015)
Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known. Aim: To assess the safety profile and ...
Evolving Metformin Treatment Strategies in Type-2 Diabetes: From Immediate-Release Metformin Monotherapy to Extended- Release Combination Therapy
(Lippincott Williams & Wilkins, 2014-05-01)
Over the last 40 years, metformin has revolutionized the treatment of type-2 diabetes worldwide and is still the most influential oral antidiabetic drug today. International guidelines now recommend that patients with ...
Metabolic Surgery for Non-Obese Type 2 Diabetes Incretins, Adipocytokines, and Insulin Secretion/Resistance Changes in a 1-Year Interventional Clinical Controlled Study
(Lippincott Williams & WilkinsPhiladelphiaEUA, 2012)
Safety and efficacy of vildagliptin in real life chilean diabetic patients Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2
(Sociedad Medica de Santiago, 2015)
© 2015, Sociedad Medica de Santiago. All rights reserved. Background: Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not ...
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
(MDPI, 2021)
Type 2 Diabetes Mellitus (T2DM) is one of the most prevalent chronic metabolic disorders, and insulin has been placed at the epicentre of its pathophysiological basis. However, the involvement of impaired alpha (α) cell ...
Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?
(MDPI, 2021)
The prevalence of type 2 diabetes mellitus worldwide stands at nearly 9.3% and it is estimated that 20–40% of these patients will develop diabetic kidney disease (DKD). DKD is the leading cause of chronic kidney disease ...